Serum and intratumoural GH and IGF-I concentrations: Prognostic factors in the outcome of canine mammary cancer

Research in Veterinary Science

Volumn 89, Issue 3, 2010, Pages 396-403

  Queiroga, Felisbina L ^b   Pérez Alenza, Dolores ^a   Silvan, Gema ^a   Peña, Laura ^a   Lopes, Carlos S ^c   Illera, Juan C ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Autocrine; Breast cancer; Canine mammary tumours; Enzyme immunoassay; GH; GH IGF I axis; IGF I; Serum; Tissue

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOG; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; HORMONE DETERMINATION; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENT CANCER; SURVIVAL TIME; TUMOR CLASSIFICATION; TUMOR LOCALIZATION;

ANIMALS; BREAST; BREAST NEOPLASMS; DOG DISEASES; DOGS; ESTROGEN RECEPTOR ALPHA; FEMALE; GROWTH HORMONE; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR I; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS;

CANIDAE; CANIS FAMILIARIS;

EID: 78049317978     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2010.03.016     Document Type: Article

References (77)

1. Barni S., Lissoni P., Brivio F., Fumagalli L., Merlini D., Cataldo M., Rovelli F., Tancini G. Serum concentrations of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin. Tumori 1994, 80:212-215.
2. Baumann G.P. Growth hormone isoforms. Growth Hormone & IGF Research 2009, 19:333-340.
3. Chong Y.M., Subramanian A., Sharma A.K., Mokbel K. The potential clinical applications of insulin-like growth factor-1 ligand in human breast cancer. Anticancer Research 2007, 27:1617-1624.
4. Cohen P., Clemmons D.R., Rosenfeld R.G. Does the GH-IGF axis play a role in cancer pathogenesis?. Growth Hormone & IGF Research 2000, 10:297-305.
5. Coşkun U., Günel N., Sancak B., Günel U., Onuk E., Bayram O., Yílmaz E., Candan S., Ozkan S. Significance of serum vascular endothelial growth factor, insulin-like growth factor-I concentrations and nitric oxide activity in breast cancer patients. Breast 2003, 12:104-110.
6. Divisova J., Kuiatse I., Lazard Z., Weiss H., Vreeland F., Hadsell D.L., Schiff R., Osborne C.K., Lee A.V. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Research and Treatment 2006, 98:315-327.
7. Drake W.M., Trainer P.J. Clinical use of pegvisomant for the treatment of acromegaly. Treatments in Endocrinology 2003, 2:369-374.
8. Emerman J.T., Leahy M., Gout P.W., Bruchovsky N. Elevated growth hormone concentrations in sera from breast cancer patients. Hormone and Metabolic Research 1985, 17:421-424.
9. Enriori P.J., Fischer C.R., Gori J.R., Etkin A.E., Calandra R.S., Lüthy I.A. Augmented serum concentrations of the IGF-I/IGF-binding protein-3 ratio in pre-menopausal patients with type I breast cysts. European Journal of Endocrinology 2003, 148:177-184.
10. Friend K.E. Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Hormone and IGF Research 2001, 11:121-123.
11. Goffin V., Bernichtein S., Carrière O., Bennett W.F., Kopchick J.J., Kelly P.A. The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology 1999, 140:3853-3856.
12. Gooch J.L., Van Den Berg C.L., Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death - proliferative and anti-apoptotic effects. Breast Cancer Research and Treatment 1999, 56:1-10.
13. Grimberg A., Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. Journal of Cellular Physiology 2000, 183:1-9.
14. Grønbaek H., Flyvbjerg A., Mellemkjaer L., Tjønneland A., Christensen J., Sørensen H.T., Overvad K. Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. Cancer Epidemiology, Biomarkers and Prevention 2004, 13:1759-1764.
15. Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., Rosner B., Speizer F.E., Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351:1393-1396.
16. Harris J., Stanford P.M., Oakes S.R., Ormandy C.J. Prolactin and the prolactin receptor: new targets of an old hormone. Annals of Medicine 2004, 36:414-425.
17. Holdaway I.M., Mason B.H., Lethaby A.E., Singh V., Harvey V.J., Thompson P.I., Evans B.D. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer. ANZ Journal of Surgery 2003, 73:905-908.
18. Holly J.M., Gunnell D.J., Davey Smith G. Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer?. The Journal of Endocrinology 1999, 162:321-330.
19. Huynh H.T., Tetenes E., Wallace L., Pollak M. In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Research 1993, 53:1727-1730.
20. Illera, J.C., Silvan, G., Pérez-Alenza, M.D., Pena, L., 2003. The possible role of IGF-I and androgens in the development of canine inflammatory mammary carcinoma. In: Proceedings of the IV International Congress on Hormonal Carcinogenesis of the Mammary Gland, Valencia, Espana.
21. Jammes H., Peyrat J.P., Ban E., Vilain M.O., Haour F., Djiane J., Bonneterre J. Insulin-like growth factor 1 receptors in human breast tumour: localisation and quantification by histo-autoradiographic analysis. British Journal of Cancer 1992, 66:248-253.
22. Jenkins P.J., Mukherjee A., Shalet S.M. Does growth hormone cause cancer?. Clinical Endocrinology (Oxf) 2006, 64:115-121.
23. Johansson H., Baglietto L., Guerrieri-Gonzaga A., Bonanni B., Mariette F., Macis D., Serrano D., Sandri M.T., Decensi A. Factors associated with circulating concentrations of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer. Breast Cancer Research and Treatment 2004, 88:63-73.
24. Karey K.P., Sirbasku D.A. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Research 1988, 48:4083-4092.
25. Kaulsay K.K., Mertani H.C., Törnell J., Morel G., Lee K.O., Lobie P.E. Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone. Experimental Cell Research 1999, 250:35-50.
26. Kaulsay K.K., Mertani H.C., Lee K.O., Lobie P.E. Autocrine human growth hormone enhancement of human mammary carcinoma cell spreading is Jak2 dependent. Endocrinology 2000, 141:1571-1584.
27. Krajcik R.A., Borofsky N.D., Massardo S., Orentreich N. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiology, Biomarkers and Prevention 2002, 11:1566-1573.
28. Laban C., Bustin S.A., Jenkins P.J. The GH-IGF-I axis and breast cancer. Trends in Endocrinology and Metabolism 2003, 14:28-34.
29. Manni A., Wei L., Badger B., Zaenglein A., Leighton J., Shimasaki S., Ling N. Expression of messenger RNA for insulin-like growth factors and insulin-like growth factor binding proteins by experimental breast cancer and normal breast tissue in vivo. Endocrinology 1992, 130:1744-1746.
30. Mertani H.C., Garcia-Caballero T., Lambert A., Gérard F., Palayer C., Boutin J.M., Vonderhaar B.K., Waters M.J., Lobie P.E., Morel G. Cellular expression of growth hormone and prolactin receptors in human breast disorders. International Journal of Cancer 1998, 79:202-211.
31. Misdorp, W., Else, R.W., Hellmen, E., Lipscomb, T.P., 1999. Histological Classification of Mammary Tumors of the Dog and Cat. Second Series, vol. 7. Armed Forces Institute of Pathology and World Health Organization, Washington.
32. Mol J.A., van Garderen E., Selman P.J., Wolfswinkel J., Rijinberk A., Rutteman G.R. Growth hormone mRNA in mammary gland tumors of dogs and cats. The Journal of Clinical Investigation 1995, 95:2028-2034.
33. Mol J.A., Henzen-Logmans S.C., Hageman P., Misdorp W., Blankenstein M.A., Rijnberk A. Expression of the gene encoding growth hormone in the human mammary gland. The Journal of Clinical Endocrinology and Metabolism 1995, 80:3094-3096.
34. Mol J.A., Lantinga-van Leeuwen I.S., van Garderen E., Selman P.J., Oosterlaken-Dijksterhuis M.A., Schalken J.A., Rijnberk A. Mammary growth hormone and tumorigenesis - lessons from the dog. Veterinary Quartile 1999, 21:111-115.
35. Mukhina S., Mertani H.C., Guo K., Lee K.O., Gluckman P.D., Lobie P.E. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:15166-15171.
36. Muller A.F., Janssen J.A., de Herder W.W., van der Lely A.J. Growth hormone receptor antagonists: potential indications. Nederlands Tijdschrift voor Geneeskunde 2001, 145:69-73.
37. Ng E.H., Ji C.Y., Tan P.H., Lin V., Soo K.C., Lee K.O. Altered serum concentrations of insulin-like growth-factor binding proteins in breast cancer patients. Annals of Surgical Oncology 1998, 5:194-201.
38. Ogilvy-Stuart A.L., Gleeson H. Cancer risk following growth hormone use in childhood: implications for current practice. Drug Safety 2004, 27:369-382.
39. Oosterlaken-Dijksterhuis M.A., Kwant M.M., Slob A., Hellmen E., Mol J.A. IGF-I and retinoic acid regulate the distribution pattern of IGFBPs synthesized by the canine mammary tumour cell line CMT-U335. Breast Cancer Research and Treatment 1999, 54:11-23.
40. Owen, L.N., 1980. TMN Classification of Tumors in Domestic Animals. ED, VPH/CMO/80.20, World Health Organization, Geneva.
41. Paisley A.N., Trainer P., Drake W. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly. Expert Opinion on Biological Therapy 2004, 4:421-425.
42. Peña L., Perez-Alenza M.D., Rodriguez-Bertos A., Nieto A. Canine inflammatory mammary carcinoma: histopathology, immunohistochemistry and clinical implications of 21 cases. Breast Cancer Research and Treatment 2003, 78:141-148.
43. Perez-Alenza M.D., Peña L., del Castillo N., Nieto A.I. Factors influencing the incidence and prognosis of canine mammary tumours. Journal of Small Animal Practice 2000, 41:287-291.
44. Perry J.K., Mohankumar K.M., Emerald B.S., Mertani H.C., Lobie P.E. The contribution of growth hormone to mammary neoplasia. Journal of Mammary Gland Biology and Neoplasia 2008, 13:131-145.
45. Peyrat J.P., Bonneterre J., Hecquet B., Vennin P., Louchez M.M., Fournier C., Lefebvre J., Demaille A. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. European Journal of Cancer 1993, 29:492-497.
46. Pollak M.N. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Research and Treatment 1998, 47:209-217.
47. Pollak M., Costantino J., Polychronakos C., Blauer S.A., Guyda H., Redmond C., Fisher B., Margolese R. Effect of tamoxifen on serum insulinlike growth factor I concentrations in stage I breast cancer patients. Journal of the National Cancer Institute 1990, 82:1693-1697.
48. Queiroga F.L., Perez-Alenza M.D., Silvan G., Pena L., Lopes C., Illera J.C. Cox-2 concentrations in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance. Anticancer Research 2005, 25:4269-4275.
49. Queiroga F.L., Alves A., Pires I., Lopes C. Expression of Cox-1 and Cox-2 in canine mammary tumours. Journal of Comparative Pathology 2007, 136:177-185.
50. Queiroga F.L., Perez-Alenza M.D., Silvan G., Pena L., Lopes C.S., Illera J.C. Crosstalk between GH/IGF-I axis and steroid hormones (progesterone, 17β-estradiol) in canine mammary tumours. Journal of Steroid Biochemistry and Molecular Biology 2008, 110:76-82.
51. Raccurt M., Lobie P.E., Moudilou E., Garcia-Caballero T., Frappart L., Morel G., Mertani H.C. High stromal and epithelial human gh gene expression is associated with proliferative disorders of the mammary gland. Journal of Endocrinology 2002, 175:307-318.
52. Rijnberk A., Kooistra H.S., Mol J.A. Endocrine diseases in dogs and cats: similarities and differences with endocrine diseases in humans. Growth Hormone & IGF Research 2003, 13:158-164.
53. Rosfjord E.C., Dickson R.B. Growth factors, apoptosis, and survival of mammary epithelial cells. Journal of Mammary Gland Biology and Neoplasia 1999, 4:229-237.
54. Rutteman G.R., Misdorp W., Van den Brom W.E., Rijnberk A. Anterior pituitary function in female dogs with spontaneous mammary tumors: I. Growth hormone. Anticancer Research 1989, 9:235-239.
55. Selman P.J., Mol J.A., Rutteman G.R., van Garderen E., Rijnberk A. Progestin-induced growth hormone excess in the dog originates in the mammary gland. Endocrinology 1994, 134:287-292.
56. Shim M., Cohen P. IGFs and human cancer: implications regarding the risk of growth hormone therapy. Hormone Research 1999, 51:42-51.
57. Shin A., Ren Z., Shu X.O., Cai Q., Gao Y.T., Zheng W. Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Research and Treatment 2007, 105:55-61.
58. Singer C.F., Mogg M., Koestler W., Pacher M., Marton E., Kubista E., Schreiber M. Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size. Clinical Cancer Research 2004, 10:4003-4009.
59. Sisci D., Surmacz E. Crosstalk between IGF signaling and steroid hormone receptors in breast cancer. Current Pharmaceutical Design 2007, 13:705-717.
60. Surmacz E. Function of the IGF-I receptor in breast cancer. Journal of Mammary Gland Biology and Neoplasia 2000, 5:95-105.
61. Szepeshazi K., Schally A.V., Armatis P., Groot K., Hebert F., Feil A., Varga J.L., Halmos G. Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology 2001, 142:4371-4378.
62. Tallet E., Rouet V., Jomain J.B., Kelly P.A., Bernichtein S., Goffin V. Rational design of competitive prolactin/growth hormone receptor antagonists. Journal of Mammary Gland Biology and Neoplasia 2008, 13:105-117.
63. Toniolo P., Bruning P.F., Akhmedkhanov A., Bonfrer J.M., Koenig K.L., Lukanova A., Shore R.E., Zeleniuch-Jacquotte A. Serum insulin-like growth factor-I and breast cancer. International Journal of Cancer 2000, 88:828-832.
64. Toropainen E., Lipponen P., Syrjänen K. Expression of insulin-like growth factor I (IGF-I) in female breast cancer as related to established prognostic factors and long-term prognosis. European Journal of Cancer 1995, 31:1443-1448.
65. van der Lely A.J. The future of growth hormone antagonists. Current Opinion in Pharmacology 2002, 2:730-733.
66. van der Lely A.J., Kopchick J.J. Growth hormone receptor antagonists. Neuroendocrinology 2006, 83:264-268.
67. van Garderen E., Schalken J.A. Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system. Molecular and Cellular Endocrinology 2002, 197:153-165.
68. van Garderen E., de Wit M., Voorhout W.F., Rutteman G.R., Mol J.A., Nederbragt H., Misdorp W. Expression of growth hormone in canine mammary tissue and mammary tumors. Evidence for a potential autocrine/paracrine stimulatory loop. American Journal of Pathology 1997, 150:1037-1047.
69. van Garderen E., van der Poel H.J., Swennenhuis J.F., Wissink E.H., Rutteman G.R., Hellmen E., Mol J.A., Schalken J.A. Expression and molecular characterization of the growth hormone receptor in canine mammary tissue and mammary tumors. Endocrinology 1999, 140:5907-5914.
70. van Garderen E., Swennenhuis J.F., Hellmén E., Schalken J.A. Growth hormone induces tyrosyl phosphorylation of the transcription factors Stat5a and Stat5b in CMT-U335 canine mammary tumor cells. Domestic Animal Endocrinology 2001, 20:123-135.
71. Voskuil D.W., Bosma A., Vrieling A., Rookus M.A., van 't Veer L.J. Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Research and Treatment 2004, 84:225-233.
72. Waters M.J. Seeking SOCS and sex steroids. Trends in Endocrinology and Metabolism 2003, 14:149-151.
73. Wennbo H., Törnell J. The role of prolactin and growth hormone in breast cancer. Oncogene 2000, 19:1072-1076.
74. Yakar S., Pennisi P., Kim C.H., Zhao H., Toyoshima Y., Gavrilova O., LeRoith D. Studies involving the GH-IGF axis: lessons from IGF-I and IGF-I receptor gene targeting mouse models. Journal of Endocrinological Investigation 2005, 28:19-22.
75. Yin D., Vreeland F., Schaaf L.J., Millham R., Duncan B.A., Sharma A. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clinical Cancer Research 2007, 13:1000-1009.
76. Yu H., Levesque M.A., Khosravi M.J., Papanastasiou-Diamandi A., Clark G.M., Diamandis E.P. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. British Journal of Cancer 1996, 74:1242-1247.
77. Zhu T., Starling-Emerald B., Zhang X., Lee K.O., Gluckman P.D., Mertani H.C., Lobie P.E. Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Research 2005, 65:317-324.